{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:15Z","timestamp":1783161435698,"version":"3.54.6"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>(1) Kinase inhibitors (KI) targeting components of the DNA damage repair pathway are a promising new type of drug. Combining them with ionizing radiation therapy (IR), which is commonly used for treatment of head and neck tumors, could improve tumor control, but could also increase negative side effects on surrounding normal tissue. (2) The effect of KI of the DDR (ATMi: AZD0156; ATRi: VE-822, dual DNA-PKi\/mTORi: CC-115) in combination with IR on HPV-positive and HPV-negative HNSCC and healthy skin cells was analyzed. Cell death and cell cycle arrest were determined using flow cytometry. Additionally, clonogenic survival and migration were analyzed. (3) Studied HNSCC cell lines reacted differently to DDRi. An increase in cell death for all of the malignant cells could be observed when combining IR and KI. Healthy fibroblasts were not affected by simultaneous treatment. Migration was partially impaired. Influence on the cell cycle varied between the cell lines and inhibitors; (4) In conclusion, a combination of DDRi with IR could be feasible for patients with HNSCC. Side effects on healthy cells are expected to be limited to normal radiation-induced response. Formation of metastases could be decreased because cell migration is impaired partially. The treatment outcome for HPV-negative tumors tends to be improved by combined treatment.<\/jats:p>","DOI":"10.3390\/genes12060925","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:20:26Z","timestamp":1623928826000},"page":"925","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells"],"prefix":"10.3390","volume":"12","author":[{"given":"Eva-Maria","family":"Faulhaber","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-3774","authenticated-orcid":false,"given":"Tina","family":"Jost","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Symank","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Scheper","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"B\u00fcrkel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-216X","authenticated-orcid":false,"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-3226","authenticated-orcid":false,"given":"Luitpold V.","family":"Distel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/13543784.2017.1389895","article-title":"Directing the use of DDR kinase inhibitors in cancer treatment","volume":"26","author":"Brandsma","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"81662","DOI":"10.18632\/oncotarget.20953","article-title":"Novel DNA targeted therapies for head and neck cancers: Clinical potential and biomarkers","volume":"8","author":"Glorieux","year":"2017","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/MCB.01243-06","article-title":"RAD18 and Poly(ADP-Ribose) Polymerase Independently Suppress the Access of Nonhomologous End Joining to Double-Strand Breaks and Facilitate Homologous Recombination-Mediated Repair","volume":"27","author":"Saberi","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.chembiol.2014.11.013","article-title":"DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics","volume":"22","author":"Srivastava","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.2174\/0929867323666161214114948","article-title":"Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions","volume":"24","author":"Basourakos","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-Human Phase I Study of a Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) in Advanced Malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_8","first-page":"1","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and Radiation Therapy: Current Advances and Future Directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_10","first-page":"1","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.2017.489","article-title":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients","volume":"118","author":"Hecht","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: Molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Castilho, R.M., Squarize, C.H., and Almeida, L.O. (2017). Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071506"},{"key":"ref_14","first-page":"775","article-title":"Radiotherapy and the cellular DNA damage response: Current and future perspectives on head and neck cancer treatment","volume":"3","author":"Fabbrizi","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21037\/atm.2016.03.34","article-title":"The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications","volume":"4","author":"Economopoulou","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22203","DOI":"10.18632\/oncotarget.14729","article-title":"Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/450179","article-title":"Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma","volume":"2012","author":"Du","year":"2012","journal-title":"J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA Repair."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"B\u00fcrkel, F., Jost, T., Hecht, M., Heinzerling, L., Fietkau, R., and Distel, L. (2020). Dual mTOR\/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239321"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Weigert, V., Jost, T., Hecht, M., Knippertz, I., Heinzerling, L., Fietkau, R., and Distel, L.V. (2020). PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07190-9"},{"key":"ref_21","first-page":"703","article-title":"Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer","volume":"53","author":"Kang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.14712\/fb2016062040167","article-title":"Comparison of the Radiosensitizing Effect of ATR, ATM and DNA-PK Kinase Inhibitors on Cervical Carcinoma Cells","volume":"62","author":"Pejchal","year":"2016","journal-title":"Folia Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00066-014-0698-x","article-title":"Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy","volume":"190","author":"Merten","year":"2014","journal-title":"Strahlenther. Onkol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","article-title":"Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy","volume":"31","author":"Satzger","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00066-020-01666-0","article-title":"FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro","volume":"197","author":"Mohamed","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00066-020-01708-7","article-title":"Synergistic effect of PAF inhibition and X-ray irradiation in non-small cell lung cancer cells","volume":"197","author":"Chen","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_27","first-page":"1728","article-title":"Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation","volume":"15","author":"Hecht","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2307\/3572419","article-title":"Cyclic X-ray Responses in Mammalian Cellsin Vitro","volume":"33","author":"Sinclair","year":"1968","journal-title":"Radiat. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13014-017-0827-7","article-title":"Idelalisib may have the potential to increase radiotherapy side effects","volume":"12","author":"Gryc","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.radonc.2020.01.016","article-title":"Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel\/cisplatin to standard radiotherapy with fluorouracil\/cisplatin: The PacCis-trial","volume":"144","author":"Fietkau","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Torrisi, F., Minafra, L., Cammarata, F.P., Savoca, G., Calvaruso, M., Vicario, N., Maccari, L., P\u00e9r\u00e8s, E.A., \u00d6z\u00e7elik, H., and Bernaudin, M. (2020). SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113917"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.2144\/000112757","article-title":"Increased efficiency for performing colony formation assays in 96-well plates: Novel applications to combination therapies and high-throughput screening","volume":"44","author":"Katz","year":"2008","journal-title":"Biotechniques"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI95148","article-title":"Mechanisms and functions of cellular senescence","volume":"128","author":"Herranz","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_36","first-page":"74","article-title":"Cellular senescence: What, why, and how","volume":"29","author":"Regulski","year":"2017","journal-title":"Wounds"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dobler, C., Jost, T., Hecht, M., Fietkau, R., and Distel, L. (2020). Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells. Cells, 9.","DOI":"10.3390\/cells9092012"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature03098","article-title":"Intrinsic tumour suppression","volume":"432","author":"Lowe","year":"2004","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/sj.onc.1210268","article-title":"Irradiation-induced G2\/M checkpoint response requires ERK1\/2 activation","volume":"26","author":"Yan","year":"2007","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cdd.4400402","article-title":"Irradiation induces G2\/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression","volume":"5","author":"Hartmann","year":"1998","journal-title":"Cell Death Differ."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood-2003-07-2527","article-title":"A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia","volume":"103","author":"Willmore","year":"2004","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1158\/0008-5472.CAN-05-4275","article-title":"Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441","volume":"66","author":"Zhao","year":"2006","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-05-0358","article-title":"Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage","volume":"5","author":"Sturgeon","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","first-page":"74","article-title":"The effect of ATM and ERK1\/2 inhibition on mitoxantrone-induced cell death of leukaemic cells","volume":"57","author":"Havelek","year":"2011","journal-title":"Folia Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1593\/neo.09986","article-title":"Naphthalimides Induce G2 Arrest through the ATM-Activated Chk2-Executed Pathway in HCT116 Cells","volume":"11","author":"Zhu","year":"2009","journal-title":"Neoplasia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/0008-5472.CAN-07-0675","article-title":"DNA Protein Kinase\u2013Dependent G2 Checkpoint Revealed following Knockdown of Ataxia-Telangiectasia Mutated in Human Mammary Epithelial Cells","volume":"68","author":"Arlander","year":"2008","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: Therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/ijd.13371","article-title":"Radiation dermatitis: An overview","volume":"56","author":"Hegedus","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fonc.2017.00089","article-title":"Radiation-Induced Oral Mucositis","volume":"7","author":"Maria","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hecht, M., Hahn, D., Wolber, P., Hautmann, M.G., Reichert, D., Weniger, S., Belka, C., Bergmann, T., G\u00f6hler, T., and Welslau, M. (2020). Treatment response lowers tumor symptom burden in recurrent and\/or metastatic head and neck cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07440-w"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00405-020-06118-0","article-title":"Predictors for distant metastasis in head and neck cancer, with emphasis on age","volume":"278","author":"Muntinghe","year":"2021","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1615\/CritRevEukarGeneExpr.v21.i2.40","article-title":"Molecular Parameters of Head and Neck Cancer Metastasis","volume":"21","author":"Bhave","year":"2011","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.14639\/0392-100X-suppl.1-40-2020","article-title":"Metastatic disease in head & neck oncology","volume":"40","author":"Pisani","year":"2020","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0092-8674(00)81280-5","article-title":"Cell Migration: A Physically Integrated Molecular Process","volume":"84","author":"Lauffenburger","year":"1996","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcell.2019.00107","article-title":"In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis","volume":"7","author":"Pijuan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_58","unstructured":"Jandial, R. (2013). Metastatic Cancer: Clinical and Biological Perspectives, Landes Bioscience."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1038\/s41467-020-18580-9","article-title":"ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration","volume":"11","author":"Kidiyoor","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1667\/RR13515.1","article-title":"DNA Damage Response Genes and the Development of Cancer Metastasis","volume":"181","author":"Broustas","year":"2014","journal-title":"Radiat. Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yang, H., Yao, F., Marti, T.M., Schmid, R.A., and Peng, R.-W. (2020). Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. Cancers, 12.","DOI":"10.3390\/cancers12113389"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107617","DOI":"10.1016\/j.pharmthera.2020.107617","article-title":"DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions","volume":"215","author":"Medo","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1245\/s10434-019-08043-x","article-title":"DNA Repair Protein Rad51 Induces Tumor Growth and Metastasis in Esophageal Squamous Cell Carcinoma via a p38\/Akt-Dependent Pathway","volume":"27","author":"Chiu","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mc.23168","article-title":"PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK\/ERK-induced epithelial-mesenchymal transition","volume":"59","author":"Wang","year":"2020","journal-title":"Mol. Carcinog."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/6\/925\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:17:42Z","timestamp":1760163462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/6\/925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["genes12060925"],"URL":"https:\/\/doi.org\/10.3390\/genes12060925","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}